Drug intelligence / Profile preview

SNH-118110

Development stage: Phase 1
Lead developer: ScinnoHub Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SNH-118110 is an orally administered small molecule inhibitor targeting Rearranged during Transfection (RET) kinase. Developed by SinoHub Pharmaceutical (Chengdu) Co., Ltd., it is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors harboring RET alterations, including RET fusion-positive non-small cell lung cancer (NSCLC). The drug is formulated as soft capsules and aims to provide a targeted therapeutic option for patients with RET-driven malignancies by blocking oncogenic signaling pathways associated with RET fusions and mutations.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on SNH-118110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNH-118110.

Explore the full profile